Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBOVAC-Booster Study
PACTR202102484171450Phase 2Not yet recruiting
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zabdeno in Ebola virus disease (EVD), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoints: Safety and tolerability of Ad26.ZEBOV booster and Humoral immune response to Ebola glycoprotein at Day 7 and Day 21. Planned start Apr 2021; status: not yet recruiting.
02
Drugs
zabdeno
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR202102484171450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202102484171450.